Many Gram-negative and Gram-positive pathogenic microorganisms produce toxins or hemolysins that lyse eukaryotic cells and contribute to their pathogenicity (1) . The most intensively studied exotoxins produced by Gram-negative pathogens are members of the RTX family (reviewed in refs. 2 and 3). The HlyA hemolysin, present in uropathogenic Escherichia coli, is the best studied of these. HlyA increases E. coli virulence in a rodent peritonitis model (4) . Although the precise mechanism of action is unclear, it has been suggested that these toxins attenuate host phagocytic cell function (4-8). Several facultative intracellular pathogens, including rickettsiae, shigellae, Trypanosoma cruzi, and Listeria monocytogenes, escape from the phagocytic vesicle of professional phagocytic cells, but Salmonella does not (9) (10) (11) (12) . A defined role in virulence is difficult to assign to most toxins, in part because of the lack of animal models for many organisms. An exception is listeriolysin made by L. monocytogenes. The toxin dissolves the phagocytic membrane, allowing the bacteria to escape into the cytoplasm, and the bacteria are protected from the immune defenses of the host. Listeriolysin-negative mutants are avirulent (13) (14) (15) (16) (17) .
We have occasionally observed hemolysis by certain Salmonella strains, particularly low-passage clinical isolates. The gene (slyA) encoding the Salmonella hemolysin (salmolysin) has been determined by screening a Salmonella typhimurium gene bank in E. coli for hemolytic activity. Several related clones were identified, one of which was studied in detail.tt A mutation in slyA was constructed, and the mutant was found to be attenuated for both virulence in mice and growth in murine macrophages. (19, 20) and packaged into A phage particles (Stratagene). The host for the cosmid library, E. coli LE392 or DH5a (21), was grown on trypticase soy agar plates containing sheep red blood cells and tetracycline (20 ug/ml) and incubated for 36 hr at 37°C. A strongly hemolytic colony was chosen for further characterization. Subcloning, sequencing, and Southern analysis were performed by standard techniques. Hemolytic activity was subcloned on a 1.4-kb EcoRV-Cla I fragment (pSL1117). This fragment was sequenced and an open reading frame from the Cla I end was identified. Oligonucleotide primers (Fig. 1 , Oligo 1 and Oligo 3) were used to amplify a 680-bp fragment. This fragment was cloned into the EcoRV site of pSK and transformed into DH5a, and the bacteria were plated onto blood agar. Cells harboring this clone (pSL2070) were as hemolytic as those harboring pSL1117. Sequence manipulation and data-base searches were done with IBI MACVECTOR and GenBank (update 71, August 1992) .
MATERIALS AND METHODS
To complement the sly mutation in SL2161 for macrophage survival studies, the 680-bp fragment from pSL2070 was removed by HindIII/BamHI digestion, made blunt-ended with Klenow DNA polymerase, and cloned into the bluntended EcoRI site of pSC101 (22). Colonies containing the cloned salmolysin gene in pSC101 (pSL2185) were hemolytic.
Plasmid constructs were electroporated into S. typhimurium wild-type (14028s) and salmolysin mutant (SL2161) cells.
The slyA gene was mapped on the S. typhimurium chromosome by using the Mud-P22 phage of Benson and Goldman (23) . Phage were induced with mitomycin C and pelleted from the resulting lysates, and DNA was prepared for slot blots and hybridized with the PCR-amplified salmolysin structural gene. Hybridizations were done at 65°C in 6x SSPE (lx is 0.15 M NaCl/0.01 M phosphate/l mM EDTA, tTo whom reprint requests should be sent at the t address. ttThe sequence reported in this paper has been deposited in the GenBank data base (accession no. U03824). mation necessary for the hemolytic phenotype in E. coli. The deduced protein sequence was used to search a translated version of GenBank (August 1992), but no significant short homologies were found. Thus, a single gene, which we call slyA, for salmolysin, is sufficient to confer hemolytic activity on laboratory strains of E. coli.
Mapping and Conservation of the Salmolysin Gene in Salmonella. The location of the gene on the Salmonella chromosome was determined by a modification of a published procedure (23, 31) . This procedure is based on Mud-P22 hybrid phages inserted at defined locations in the Salmonella chromosome. After induction, each phage will package an -3-min contiguous portion of the Salmonella chromosome. DNA is then purified from each of these phages, bound to a membrane, and probed (see Materials and Methods). Using this procedure, we mapped the slyA gene to a region between 28.5 and 30 min. Few genes have been identified in this location, either in Salmonella or in the related region in E. coli.
DNA was extracted from the parent strain, 17 clinical Salmonella isolates, three Shigella serotypes, enteroinvasive E. coli, E. coli K-12 laboratory strains, and other pathogenic bacteria (see Materials and Methods for a list). Southern hybridization using the 680-bp fragment as a probe showed that the gene was present in all serotypes of Salmonella examined, Shigella, and enteroinvasive E. coli (Fig. 2) but not in any of the other bacterial species examined. A single 7-kb Pst I fragment hybridized to DNA from most serotypes of Salmonella. Three serotypes contained two fragments that hybridized, suggesting that the slyA gene may be duplicated in some serotypes of Salmonella (Fig. 2) . Preliminary experiments suggest that the slyA cognates in Shigella and enteroinvasive E. coli are on extrachromosomal plasmids (data not shown). These data show that the slyA gene is conserved within serogroups of Salmonella.
Biological Properties of Salmolysin. The slyA gene product was determined by using the PCR primers shown in Fig. 1 to place the coding region under the control of T7 RNA polymerase. A 519-bp fragment was amplified, cloned into pRK172, and transformed into E. coli BL21(DE3) (28) of T7 RNA polymerase) and [35S]methionine and then were separated by SDS/PAGE. A single 16-kDa protein was specifically labeled (Fig. 3) , in close agreement with the size of salmolysin predicted from the DNA sequence. To isolate functional salmolysin from E. coli containing cloned slyA (pSL1117), overnight cultures were osmotically shocked (25). Released salmolysin was partially purified by FPLC Mono Q anion-exchange chromatography (Pharmacia); all hemolytic activity was eluted at 150 mM NaCl. A 16-kDa protein, identical in size to the protein overexpressed under the control of T7 RNA polymerase, was enriched in this fraction (Fig. 3) . Identically processed osmotic-shock supernatants of E. coli with pKS alone had no protein in this size range that was eluted at 150 mM NaCl, nor was hemolytic activity detected in any fraction. Salmolysin has an isoelectric point of pI 5.5 determined by preparative isoelectric focusing. The hemolytic activity of salmolysin was found to be sensitive to heat (65°C for 15 min) and insensitive to protease inhibitors (phenylmethanesulfonyl fluoride, leupeptin, and pepstatin). Salmolysin was fully active in the presence of 50 mM EDTA, unlike the hemolysin from uropathogenic E. coli (32 is >105 for intraperitoneal administration and >109 when administered orally to mice (Table 1 ). This represents a difference of >10,000-fold intraperitoneally and >1000-fold orally. Later experiments suggested that the oral LD50 value was >2 x 1010. The salmolysin mutant is avirulent by intravenous infection at a dose of >104 bacteria.
The infection kinetics of the slyA-mutant were very different from those of wild-type Salmonella (Fig. 4) . Mice were infected orally with about 2 x 1010 organisms of wild type (14028s) or the slyA-mutant (SL2161). Within 1 day, 103-104 bacteria of the parent strain were present in the Peyer's patches and mesenteric lymph nodes, and lower but significant numbers were present in the liver and spleen. During the next 6 days, exponential growth of the parent was observed in the liver and spleen, resulting in death of the mice. In contrast to this, low numbers of SL2161 reached the mesenteric lymph nodes and Peyer's patches (about 100 versus 103-104). Lower numbers of SL2161 reached the liver and spleen as compared with the wild-type parent. The salmolysin mutant grew very poorly in the liver and somewhat more slowly in the spleen. Similar results were seen following intravenous infection (data not shown). Thus, the sly lesion is highly attenuating and the most striking effect is to render the salmolysin mutant vulnerable to some component of the liver and spleen.
Survival ofthe slyA-mutant was compared with that of the parent within peritoneal murine macrophages (Fig. 5) (26, 33, 34) . The parent strain is resistant to the bactericidal effects of macrophages, whereas a phoP mutant is extremely sensitive to these cells (18, 35, 36) . The slyA-and phoP mutants were equally sensitive in these assays, suggesting that salmolysin plays a direct role in the survival of Salmonella within macrophages. The avirulence of the slyA mutation might also be the result of polar effects on another gene required for or involved in virulence. We have addressed this possibility by complementing the slyA mutation with a plasmid construct containing the 680-bp slyA structural gene cloned in pSC101 (22) (pSL2185). Complementation with pSL2185 resulted in restoration of wild-type survival within proteose peptoneelicited mouse peritoneal macrophages as compared with the isogenic control with the vector alone (Fig. 5) . However, we were unable to complement the virulence defect of SL2161 in mice by using the same clone. Nonetheless, our results confirm that salmolysin plays a key role in the ability of Salmonella to survive and replicate within murine macrophages and that disruption of the slyA gene profoundly attenuates Salmonella virulence.
DISCUSSION
We have identified an essential virulence factor in Salmonella, salmolysin, a hemolytic toxin. This toxin is required for survival within peritoneal macrophages and for virulence in a mouse infection model. The slyA gene has no significant homologies to other reported genes, nor does it contain any readily identifiable motifs such as the RTX motif found in the E. coli hemolysin (2). slyA is present in all Salmonella, Shigella, and enteroinvasive E. coli strains but is absent from many other bacteria. of virulence genes and toxins that have been cloned in E. coli from both related and unrelated pathogens, such a putative regulatory gene has not been found. It is surprising that Salmonella strains are not obviously hemolytic on blood agar, given that they encode this potent hemolysin. One explanation for this comes from preliminary studies aimed at understanding its regulation. A transcriptional fusion of slyA to lacZ resulted in constitutive expression of lacZ in E. coli just as we observe hemolytic activity in E. coli. However, lacZ was not expressed in Salmonella from the same transcriptional fusion (data not shown). This suggests that slyA is tightly regulated in Salmonella and is probably expressed only in vivo. Using this same fusion, we have also found that expression of slyA is independent of phoP/phoQ, a major intracellular regulator, and of katF, the starvation regulator (37, 38) . That a slyA cognate is found in Shigella and enteroinvasive E. coli suggests that these bacteria may share a similar virulence mechanism, perhaps related to survival within macrophages.
We propose that salmolysin acts on the eukaryotic cell membranes, although to do so, it must be exported or become associated with the bacterial outer membrane when expressed. The protein sequence does not reveal a classic signal sequence. However, the protein product of hlyA present in certain uropathogenic E. coli strains also lacks an amionterminal signal sequence but is transported by the products of hlyB, hlyD, and tolC. Salmolysin has a significant hydrophobic region at the carboxyl-terminal end (residues 115-133) which may form a membrane-spanning a-helix. Whether this sequence could be involved in secretion or in pore formation in the target cell membrane has not been addressed experimentally.
We were unable to complement the slyA mutation in vivo in the mouse by using the slyA gene cloned in pSC101, although we were able to fully complement the mutation in bacteria in macrophages. There may be two reasons for this. Perhaps insertional inactivation ofslyA is polar on expression of other, unidentified downstream genes. This hypothesis predicts that a downstream gene(s) is required for virulence but not for survival and growth in macrophages (39). It is also possible that slyA is not correctly regulated in our construction and hence does not express salmolysin correctly in vivo.
Salmonella slyA-mutants are blocked at more than one step during in vivo infection; lower numbers of bacteria reach the Peyer's patches and mesenteric lymph nodes, and they grow less in the spleen and liver. The spleen and liver are both initially infected with about equal numbers, but the slyAmutant is cleared more rapidly from the liver than from the spleen. In course-of-infection experiments with many other attenuated mutants, we have never observed this phenotype. The slyA-mutant may be unusually susceptible to a specific factor(s) found within the liver. The difference may be due to survival within a specific macrophage population, in this case the Kupffer cell. The slyA-mutant can survive in certain macrophages (J774.1 cell line) but not in others (data not shown). Our hypothesis is that this difference in survival in diverse macrophage populations lies at the level of slyA expression. If this were true, it would suggest that Salmonella can distinguish certain differentiated macrophages and that expression of the slyA gene is critical for survival within these macrophages. That slyA is found in Salmonella, Shigella, and enteroinvasive E. coli suggests that these bacteria may share a similar virulence mechanism, perhaps related to survival within macrophages. Perhaps salmolysin plays a crucial part in defending the bacteria against the early onslaught of phagocytic cells found within the lamina propria of the intestinal mucosa.
